This page shows the latest BAN2401 news and features for those working in and with pharma, biotech and healthcare.
The study will evaluate the therapeutic effect of BAN2401 on the progression of Alzheimer’s disease (AD) in individuals in preclinical, asymptomatic stages of the disease. ... Biogen and Eisai are also currently studying BAN2401 in a pivotal phase 3
The Alzheimer’s programmes were the centrepiece of Biogen’s pipeline, and while one Eisai-partnered anti-amyloid candidate (BAN2401) remains in late-stage development with data due in 2022 there
now have only one amyloid-targeting drug left in the pipeline– a phase 3 study of amyloid-targeting candidate BAN2401, which remains unaffected by the discontinuation, with results set to read ... BAN2401 was shown to reduce disease progression by
BAN2401 has been seen as something of an also-ran in the Biogen/Eisai pipeline, particularly after reporting confusing results in a phase 2b trial last year. ... there is now a shift towards thinking about the different forms of amyloid in the brain,
The partners have a similar candidate, BAN2401, being studied in prodromal and mild Alzheimer’s patients, though its future must now also be under review.
Also considering a trial in preclinical Alzheimer’s subjects. Biogen and Eisai spent the latter half of 2018 defending phase 2b results with their Alzheimer’s disease candidate BAN2401 against sceptics, ... s disease, while BAN2401 binds to and
More from news
Approximately 2 fully matching, plus 13 partially matching documents found.
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....